Protocol Review &Monitoring System The Protocol Review &Monitoring System (PRMS) at Moffitt Cancer Center facilitates the function of two Scientific Review Committees (SRCs), each staffed with appropriate faculty and scientific representation. Each committee meets once a month, with staggered meetings so that there is an SRC meeting approximately every two weeks. The SRCs provide the review for scientific merit and prioritization and monitor scientific progress for all protocols at the Cancer Center. SRC approval is required prior to IRB submission and the IRB will not consider a research study from the Cancer Center that has not been approved by the Moffitt Cancer Center SRC. The SRCs have reviewed between 180 and 200 new protocols each year of the grant for scientific merit. Protocols that have been previously peer reviewed by recognized peer-review agencies are expedited through the SRC process, but are reviewed administratively by the Chair or his designee. The committees review all ongoing clinical research studies for scientific progress and have the authority to suspend and close studies that are not making scientific progress towards their objectives. The Cancer Center is in the process of implementing the Oncore? clinical trials management software that will aid the PRMS in the administrative tracking of all research studies (pending and ongoing), as well as facilitate the committee process by helping to coordinate the committee membership, agendas, decisions and correspondence.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA076292-13
Application #
8214126
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2011-02-01
Budget End
2012-01-31
Support Year
13
Fiscal Year
2011
Total Cost
$124,318
Indirect Cost
Name
H. Lee Moffitt Cancer Center & Research Institute
Department
Type
DUNS #
139301956
City
Tampa
State
FL
Country
United States
Zip Code
33612
Hoffman, Melissa A; Fang, Bin; Haura, Eric B et al. (2018) Comparison of Quantitative Mass Spectrometry Platforms for Monitoring Kinase ATP Probe Uptake in Lung Cancer. J Proteome Res 17:63-75
Kahen, Elliot John; Brohl, Andrew; Yu, Diana et al. (2018) Neurofibromin level directs RAS pathway signaling and mediates sensitivity to targeted agents in malignant peripheral nerve sheath tumors. Oncotarget 9:22571-22585
Gonzalez, Brian D; Small, Brent J; Cases, Mallory G et al. (2018) Sleep disturbance in men receiving androgen deprivation therapy for prostate cancer: The role of hot flashes and nocturia. Cancer 124:499-506
Puri, Sonam; Hyland, Kelly A; Weiss, Kristine Crowe et al. (2018) Prediction of chemotherapy-induced nausea and vomiting from patient-reported and genetic risk factors. Support Care Cancer 26:2911-2918
Lu, Yingchang; Beeghly-Fadiel, Alicia; Wu, Lang et al. (2018) A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. Cancer Res 78:5419-5430
Eroglu, Zeynep; Zaretsky, Jesse M; Hu-Lieskovan, Siwen et al. (2018) High response rate to PD-1 blockade in desmoplastic melanomas. Nature 553:347-350
Kasting, Monica L; Christy, Shannon M; Sutton, Steven K et al. (2018) Florida physicians' reported use of AFIX-based strategies for human papillomavirus vaccination. Prev Med 116:143-149
Phadke, Manali; Remsing Rix, Lily L; Smalley, Inna et al. (2018) Dabrafenib inhibits the growth of BRAF-WT cancers through CDK16 and NEK9 inhibition. Mol Oncol 12:74-88
Park, Jae H; Rivière, Isabelle; Gonen, Mithat et al. (2018) Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia. N Engl J Med 378:449-459
Jiang, Kun; Neill, Kevin; Cowden, Daniel et al. (2018) Expression of CAS/CSE1L, the Cellular Apoptosis Susceptibility Protein, Correlates With Neoplastic Progression in Barrett's Esophagus. Appl Immunohistochem Mol Morphol 26:552-556

Showing the most recent 10 out of 1254 publications